Merck to Hold Third-Quarter 2013 Sales and Earnings Conference Call on
WHITEHOUSE STATION, N.J. -- September 27, 2013
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold
its third-quarter 2013 sales and earnings conference call with institutional
investors and analysts at 8:00 a.m. EDT on Monday, Oct. 28. During the call,
company executives will provide an overview of Merck’s performance for the
Investors, journalists and the general public may access a live audio webcast
of the call on Merck’s website at
needed to listen to the webcast is available on Merck’s website and should be
downloaded prior to the beginning of the webcast. A replay of the webcast will
be available at approximately 11:00 a.m. EDT on Oct. 28 and will remain on the
website for 12 months. The quarter's sales and earnings news release and
supplemental financial disclosures also will be available in the Newsroom and
Investor sections of the company's website at www.merck.com.
Institutional investors and analysts can participate in the call by dialing
(706) 758-9927 or (877) 381-5782 and using ID code number 40965575.
Members of the media are invited to monitor the call by dialing (706) 758-9928
or (800) 399-7917 and using ID code number 40965575. Journalists who wish to
ask questions are requested to contact a member of Merck's Media Relations
team at the conclusion of the call.
Today's Merck is a global healthcare leader working to help the world be well.
Merck is known as MSD outside the United States and Canada. Through our
prescription medicines, vaccines, biologic therapies, and consumer care and
animal health products, we work with customers and operate in more than 140
countries to deliver innovative health solutions. We also demonstrate our
commitment to increasing access to healthcare through far-reaching policies,
programs and partnerships. For more information, visit www.merck.com and
connect with us on Twitter, Facebook and YouTube.
This news release includes “forward-looking statements” within the meaning of
the safe harbor provisions of the United States Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs and
expectations of Merck’s management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially from those set
forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of pharmaceutical industry
regulation and health care legislation in the United States and
internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market conditions;
manufacturing difficulties or delays; financial instability of international
economies and sovereign risk; dependence on the effectiveness of Merck’s
patents and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those
described in the forward-looking statements can be found in Merck’s 2012
Annual Report on Form 10-K and the company’s other filings with the Securities
and Exchange Commission (SEC) available at the SEC’s Internet site
Kelley Dougherty, 908-423-4291
Steven Cragle, 908-423-3461
Carol Ferguson, 908-423-4465
Joe Romanelli, 908-423-5185
Press spacebar to pause and continue. Press esc to stop.